References
- Sander C. A., Kind P., Kaudewitz P., Rafeld M., Jaffe E. The revised European–American classification on lymphoid neoplasms (REAL): a new perspective for the classification of cutaneous lymphomas. J. Cutan. Pathol. 1997; 24: 329–341, [PUBMED], [INFOTRIEVE], [CSA]
- Gilliam A. C., Wood G. S. Primary cutaneous lymphomas other than mycosis fungoides. Semin. Oncol. 1999; 26: 290–306, [PUBMED], [INFOTRIEVE]
- Willemze R., et al. EORTC classification for primary cutaneous lymphomas: a proposal from the cutaneous lymphoma study group of the European organization for the research and treatment of cancer. Blood 1997; 90: 355–371
- Ma D., Ariyan S. The use of isolated limb perfusion to manage recurrent malignant melanoma. Clin. Plast. Surg. 2000; 27(3)441–450, [PUBMED], [INFOTRIEVE], [CSA]
- Brobeil A., Berman C., Cruse W. Efficacy of hyperthermic isolated limb perfusion for extremity-confined recurrent melanoma. Ann. Surg. Oncol. 1998; 5(4)376–383, [PUBMED], [INFOTRIEVE], [CSA]
- Krementz E. T., Sutherland C., Davilene R. Limb perfusion in malignant melanoma. Clin. Oncol. 1984; 3(3)531–553
- Jansen R., Geel B., Zee J. Intractable cutaneous non-Hodgkin's lymphoma of the lower limb. Cancer 1989; 64: 392–395, [PUBMED], [INFOTRIEVE]
- Wilson L. D., Kacinski B., Edelson R. L., Heald P. W. Cutaneous T-cell lymphomas. Cancer Principles and Practice of Oncology, V. T. DeVita, Jr., S. Hellman, S. A. Rosenberg. Lippincott-Raven, Philadelphia 1997; 2220–2232
- World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues, E. S. Jaffe, N. L. Harris, H. Stein, J. W. Vardiman. IARC Press, Lyon 2001
- Cerroni L., Rieger E., Hodl S. Clinicopathologic and immunologic features associated with transformation of mycosis fungoides to large-cell lymphoma. Am. J. Surg. Pathol. 1992; 16: 543–552, [PUBMED], [INFOTRIEVE]
- Vonderheid E. C., Tan E. T., Kantor A. F. Long term efficacy, curative potential, and carcinogenicity of topical mechlorethamine chemotherapy and cutaneous T-cell lymphoma. J. Am. Acad. Dermatol. 1989; 20(3)416–428, [PUBMED], [INFOTRIEVE]
- Swanbeck G., Roupe G., Sandstrom M. Indications of a considerable decrease in the death rate in mycosis fungoides by PUVA treatment. Acta Dermatovenerol. 1994; 74(6)465–466
- Cotter G. W., Baglan R. J., Wasserman T. H. Palliative radiation treatment of cutaneous mycosis fungoides: a dose response. Int. J. Radiat. Oncol. Biol. Phys. 1983; 9(10)1477–1480, [PUBMED], [INFOTRIEVE]
- Reddy S., Parker C. M., Shidnia H. Total skin electron beam radiation therapy for mycosis fungoides. Am. J. Clin. Oncol. 1992; 15(2)119–124, [PUBMED], [INFOTRIEVE]
- Olsen E. A., Rosen S. T., Vollmer R. T. Interferon α2A in the treatment of cutaneous T-cell lymphomas. J. Am. Acad. Dermatol. 1989; 20(3)395–407, [PUBMED], [INFOTRIEVE]
- Zic J., Arzubiaga C., Salhany K. E. Extracorporeal photopheresis for the treatment of cutaneous T-cell lymphoma. J. Acad. Dermatol. 1992; 27: 729–736
- Kessler J. F., Jones S. E., Levine N. Isotretinoin and cutaneous helper T-cell lymphoma (mycosis fungoides). Arch. Dermatol. 1987; 123(2)201–204, [PUBMED], [INFOTRIEVE], [CROSSREF]
- Knox S. J., Levy R., Hodgkinson S. Observations on the effect of chimeric anti CD4 monoclonal antibody in patients with mycosis fungoides. Blood 1991; 77(1)20–30, [PUBMED], [INFOTRIEVE]
- Foss F. M., Borkowski T. A., Gilliom M. Chimeric fusion protein toxin DAB486IL-2 in advanced mycosis fungoides and the Sezary syndrome: correlation of activity and interleukin-2 receptor expression in a phase II study. Blood 1994; 84(6)1765–1774, [PUBMED], [INFOTRIEVE], [CSA]
- Bunn P. A., Hoffman S. J., Norris D. Systemic therapy of cutaneous T-cell lymphomas (mycosis fungoides and Sezary syndrome). Ann. Intern. Med. 1994; 121(8)592–602, [PUBMED], [INFOTRIEVE], [CSA]
- Saven A., Carrera C. J., Carson D. A. 2-Chlorodeoxyadenosine: an active agent in the treatment of cutaneous T-cell lymphoma. Blood 1992; 80(3)587–592, [PUBMED], [INFOTRIEVE]
- Von Hoff D. D., Dahlberg S., Hartstock R. J. Activity of fludarabine monophosphate in patients with advanced mycosis fungoides: a Southwest oncology group study. J. Natl. Cancer Inst. 1990; 8(12)1951–1958
- Creech O. J., Krementz E. T., Ryan R. F. Chemotherapy of cancer: regional perfusion using an extracorporeal circuit. Ann. Surg. 1958; 148: 616–620, [PUBMED], [INFOTRIEVE]
- Vaglini M., Santinami M., Nava M., Belli F., Prada A., Ammatuna M., Cascinelli N. Hyperthermic antiblastic perfusion in extracorporeal circulation: surgical technique and results in the treatment of extremities' tumor. J. Extra-corpor. Technol. 1986; 18(1)12–20
- Stehlin J. S. Hyperthermic perfusion with chemotherapy for cancer of the extremity. Surg. Gynecol. Obstet. 1969; 129(2)305–308, [PUBMED], [INFOTRIEVE]
- Ariyan S., Mitchell M. S., Kirkwood J. M. Regional isolated perfusion of high-risk melanoma of the extremities with imidazole carboxamide. Surgery 1984; 158: 238–242
- Krementz E. T., Ryan R. F. Chemotherapy of melanoma of the extremity by perfusion. Fourteen year clinical experience. Ann. Surg. 1972; 175(6)900–917, [PUBMED], [INFOTRIEVE]
- Schaadt J., Crowley R., Miller D., Kavanah M. Isolated limb perfusion: a literature review. JECT 2002; 34: 130–143